New Alzheimer's Discovery at Swiss Federal Institute of Technology Could Change Approach to Disease

Scientists at ETH Zurich have uncovered a crucial new player in Alzheimer's disease: the cellular protein GRK2. For decades, research has primarily focused on amyloid plaques and tau tangles, yielding only modest therapeutic benefits despite billions in investment. This new study, however, points to GRK2 as a potential driver of neurodegeneration.

The research team developed an experimental compound, dubbed 'Compound 10,' which appears to counteract the harmful effects of GRK2. In studies involving mice, this compound slowed the loss of nerve cells, reduced biological markers of Alzheimer's, and increased survival rates. While the research is in its early stages, it suggests that protecting cells from stress and energy failure may be as vital as targeting protein deposits.

The project began nearly two decades ago when Professor Ursula Quitterer received brain tissue samples from patients at Ain Shams University Hospital in Cairo. Comparing tissue from dementia patients and healthy individuals, Quitterer and her colleagues sought molecular differences that could reveal previously unknown disease factors. Their investigation ultimately led them to GRK2, a protein critical for regulating cellular responses to signals and stress.

"Alzheimer's is a very complex disease, and current treatments do not cure it, usually only slowing its progression for a few months," Quitterer stated. "Therefore, it is extremely important that we have now identified a new target protein, GRK2, and an active component that works via GRK2 and thus through a different mechanism than current Alzheimer's drugs."

“

Alzheimer's is a very complex disease, and current treatments do not cure it, usually only slowing its progression for a few months. Therefore, it is extremely important that we have now identified a new target protein, GRK2, and an active component that works via GRK2 and thus through a different mechanism than current Alzheimer's drugs.